JP2015518873A - 調節された放出をもたらす可溶性の且つ活性の医薬的成分の水性ゲル化組成物 - Google Patents

調節された放出をもたらす可溶性の且つ活性の医薬的成分の水性ゲル化組成物 Download PDF

Info

Publication number
JP2015518873A
JP2015518873A JP2015515528A JP2015515528A JP2015518873A JP 2015518873 A JP2015518873 A JP 2015518873A JP 2015515528 A JP2015515528 A JP 2015515528A JP 2015515528 A JP2015515528 A JP 2015515528A JP 2015518873 A JP2015518873 A JP 2015518873A
Authority
JP
Japan
Prior art keywords
composition
peptide
alkyl
weight
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2015515528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518873A5 (cg-RX-API-DMAC7.html
Inventor
マリー−マドレーヌ・バロネ
ジョエル・リシャール
ナタリー・モンドリー
ディディエ・ヌーリッソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Publication of JP2015518873A publication Critical patent/JP2015518873A/ja
Publication of JP2015518873A5 publication Critical patent/JP2015518873A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2015515528A 2012-06-08 2013-06-06 調節された放出をもたらす可溶性の且つ活性の医薬的成分の水性ゲル化組成物 Abandoned JP2015518873A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12290189.5 2012-06-08
EP12290189.5A EP2705835A1 (en) 2012-06-08 2012-06-08 Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
PCT/EP2013/061732 WO2013182653A1 (en) 2012-06-08 2013-06-06 Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release

Publications (2)

Publication Number Publication Date
JP2015518873A true JP2015518873A (ja) 2015-07-06
JP2015518873A5 JP2015518873A5 (cg-RX-API-DMAC7.html) 2016-07-14

Family

ID=48577065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015515528A Abandoned JP2015518873A (ja) 2012-06-08 2013-06-06 調節された放出をもたらす可溶性の且つ活性の医薬的成分の水性ゲル化組成物

Country Status (7)

Country Link
US (2) US20150157719A1 (cg-RX-API-DMAC7.html)
EP (2) EP2705835A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015518873A (cg-RX-API-DMAC7.html)
CN (1) CN104487049A (cg-RX-API-DMAC7.html)
HK (1) HK1208171A1 (cg-RX-API-DMAC7.html)
RU (1) RU2014153760A (cg-RX-API-DMAC7.html)
WO (1) WO2013182653A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3539551T (pt) 2011-12-29 2021-11-04 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados ao recetor de melanocortina-4 em portadores heterozigóticos
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
CA3209602A1 (en) 2013-03-15 2014-09-18 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
CN105837661B (zh) 2005-07-08 2024-10-15 益普生制药股份有限公司 黑皮质素受体配体
AR063120A1 (es) * 2006-10-05 2008-12-30 Panacea Biotec Ltd Composiciones inyectables de deposito y proceso para prepararlas
EP2148692B1 (en) 2007-05-25 2017-01-25 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
WO2009151714A2 (en) * 2008-03-24 2009-12-17 Palatin Technologies, Inc. Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
ES2654147T3 (es) * 2009-11-16 2018-02-12 Ipsen Pharma S.A.S. Composiciones farmacéuticas de ligandos del receptor de melanocortina
EP2720684B1 (en) * 2011-06-14 2019-01-16 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as the active ingredient

Also Published As

Publication number Publication date
US20170035884A1 (en) 2017-02-09
WO2013182653A1 (en) 2013-12-12
HK1208171A1 (en) 2016-02-26
US20150157719A1 (en) 2015-06-11
EP2705835A1 (en) 2014-03-12
RU2014153760A (ru) 2016-08-10
CN104487049A (zh) 2015-04-01
EP2858626A1 (en) 2015-04-15

Similar Documents

Publication Publication Date Title
Rivier et al. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists
CN104093399B (zh) 鲁棒性控释肽制剂
ES2458992T3 (es) Formulaciones de análogos de GnRH
CA2906782A1 (en) Pharmaceutical compositions
AU2012270024B2 (en) A sustained -release composition containing a melanocortin receptor ligand as the active ingredient
JP2019073564A (ja) ランレオチドの持続放出用の医薬組成物
JP2015518873A (ja) 調節された放出をもたらす可溶性の且つ活性の医薬的成分の水性ゲル化組成物
KR20120059520A (ko) 이상지질혈증을 치료하기 위한 멜라노코르틴의 용도
ES2515097T3 (es) Formulación de liberación sostenida que comprende un análogo de somatostatina
CN104487050B (zh) 促生长素抑制素受体激动剂制剂
US20190290726A1 (en) Protein polymer fusions for subcutaneous delivery of small molecules
JP2019520336A5 (cg-RX-API-DMAC7.html)
HK1194996B (en) A sustained -release composition containing a melanocortin receptor ligand as the active ingredient
WO2015063102A1 (en) Alpha-msh analogues for use in bullous disease
RU2025100211A (ru) Способы лечения ожирения агонистом mc4r
WO2015063099A1 (en) Alpha-msh analogues for use in the treatment of hailey-hailey disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160524

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20170123